490 related articles for article (PubMed ID: 26189689)
21. Metastasectomy for visceral and skeletal oligorecurrent prostate cancer.
Battaglia A; Devos G; Decaestecker K; Witters M; Moris L; Van den Broeck T; Berghen C; Everaerts W; Albersen M; Tsaturyan A; De Meerleer G; Van Poppel H; Goffin K; Ost P; Tosco L; Joniau S
World J Urol; 2019 Aug; 37(8):1543-1549. PubMed ID: 30859274
[TBL] [Abstract][Full Text] [Related]
22. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM
Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241
[TBL] [Abstract][Full Text] [Related]
23. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer.
Patel PH; Chaw CL; Tree AC; Sharabiani M; van As NJ
World J Urol; 2019 Dec; 37(12):2615-2621. PubMed ID: 31346760
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.
Muldermans JL; Romak LB; Kwon ED; Park SS; Olivier KR
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):696-702. PubMed ID: 27131082
[TBL] [Abstract][Full Text] [Related]
26. Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: A retrospective case series.
Leonetti A; D'Abbiero N; Baldari G; Andreani S; Ruffini L; Viansone AA; Buti S
Int J Urol; 2018 Oct; 25(10):879-886. PubMed ID: 30103254
[TBL] [Abstract][Full Text] [Related]
27. Clinical Outcomes of Stereotactic Body Radiotherapy With Immediate Versus Delayed Hormone Therapy in Men With Oligometastatic Recurrence of Prostate Cancer.
Chaw CL; deSouza NM; Khoo V; Suh YE; van As N
Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):509-517. PubMed ID: 32423621
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience.
Francolini G; Desideri I; Detti B; Di Cataldo V; Masi L; Caramia G; Visani L; Terziani F; Muntoni C; Lo Russo M; Loi M; Livi L
Cancer Treat Res Commun; 2019; 19():100124. PubMed ID: 30851645
[TBL] [Abstract][Full Text] [Related]
29. Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis.
Nicosia L; Franzese C; Mazzola R; Franceschini D; Rigo M; D'agostino G; Corradini S; Alongi F; Scorsetti M
Strahlenther Onkol; 2020 Mar; 196(3):213-221. PubMed ID: 31559480
[TBL] [Abstract][Full Text] [Related]
30. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
[TBL] [Abstract][Full Text] [Related]
31. Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.
Deek MP; Yu C; Phillips R; Song DY; Deville C; Greco S; DeWeese TL; Antonarakis ES; Markowski M; Paller C; Denmeade S; Carducci M; Walsh PC; Pienta KJ; Eisenberger M; Tran PT
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):948-956. PubMed ID: 31419509
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial.
David S; Tan J; Savas P; Bressel M; Kelly D; Foroudi F; Loi S; Siva S
Breast; 2020 Feb; 49():55-62. PubMed ID: 31734589
[TBL] [Abstract][Full Text] [Related]
33. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.
Ost P; Bossi A; Decaestecker K; De Meerleer G; Giannarini G; Karnes RJ; Roach M; Briganti A
Eur Urol; 2015 May; 67(5):852-63. PubMed ID: 25240974
[TBL] [Abstract][Full Text] [Related]
34. Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer.
De Bleser E; Tran PT; Ost P
Curr Opin Urol; 2017 Nov; 27(6):587-595. PubMed ID: 28816714
[TBL] [Abstract][Full Text] [Related]
35. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
36. Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis.
Franzese C; Di Brina L; D'Agostino G; Franceschini D; Comito T; De Rose F; Tozzi A; Navarria P; Scorsetti M
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2469-2479. PubMed ID: 31444549
[TBL] [Abstract][Full Text] [Related]
37. PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study.
Mazzola R; Cuccia F; Pastorello E; Salgarello M; Francolini G; Livi L; Triggiani L; Magrini SM; Ingrosso G; Aristei C; Franzese C; Scorsetti M; Alongi F
Clin Exp Metastasis; 2022 Jun; 39(3):443-448. PubMed ID: 35266063
[TBL] [Abstract][Full Text] [Related]
38. Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis.
Onal C; Gultekin M; Oymak E; Guler OC; Yilmaz MT; Yuce Sari S; Akkus Yildirim B; Yildiz F
Int J Gynecol Cancer; 2020 Jun; 30(6):865-872. PubMed ID: 32273293
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
Rii J; Sakamoto S; Yamada Y; Takeshita N; Yamamoto S; Sazuka T; Imamura Y; Nakamura K; Komiya A; Komaru A; Fukasawa S; Nakatsu H; Akakura K; Ichikawa T
Prostate; 2020 Aug; 80(11):850-858. PubMed ID: 32501559
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases.
Fanetti G; Marvaso G; Ciardo D; Rese A; Ricotti R; Rondi E; Comi S; Cattani F; Zerini D; Fodor C; de Cobelli O; Orecchia R; Jereczek-Fossa BA
Med Oncol; 2018 Apr; 35(5):75. PubMed ID: 29671075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
